A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
…, B Wörmann, WD Ludwig, U Dührsen… - Blood, The Journal …, 2008 - ashpublications.org
There is no generally established prognostic index for patients with mantle cell lymphoma (MCL),
because the International Prognostic Index (IPI) and Follicular Lymphoma International …
because the International Prognostic Index (IPI) and Follicular Lymphoma International …
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure …
G Lenz, M Dreyling, E Hoster, B Wörmann… - Journal of Clinical …, 2005 - ascopubs.org
Purpose Mantle cell lymphoma (MCL) is characterized by a poor prognosis with a low to
moderate sensitivity to chemotherapy and a median survival of only 3 to 4 years. In an attempt to …
moderate sensitivity to chemotherapy and a median survival of only 3 to 4 years. In an attempt to …
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
P Hillmen, P Muus, U Dührsen… - Blood, The Journal …, 2007 - ashpublications.org
Hemolysis and hemoglobinemia contribute to serious clinical sequelae in hemolytic disorders.
In paroxysmal nocturnal hemoglobinuria (PNH) patients, hemolysis can contribute to …
In paroxysmal nocturnal hemoglobinuria (PNH) patients, hemolysis can contribute to …
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
…, M Pfreundschuh, C Scheid, U Dührsen… - Blood, The Journal …, 2012 - ashpublications.org
In patients with multiple myeloma (MM), risk stratification by chromosomal abnormalities
may enable a more rational selection of therapeutic approaches. In the present study, we …
may enable a more rational selection of therapeutic approaches. In the present study, we …
Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non–germinal center B-cell diffuse large B …
…, SP Yeh, A Lopez-Hernandez, U Dührsen… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Ibrutinib has shown activity in non–germinal center B-cell diffuse large B-cell
lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus …
lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus …
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA
…, EJ Moding, MS Esfahani, CL Liu, U Dührsen… - Nature …, 2021 - nature.com
Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell …
…, K Bouabdallah, C Sebban, T Fischer, U Dührsen… - The Lancet, 2016 - thelancet.com
Background Mantle cell lymphoma is characterised by a poor long-term prognosis. The
European Mantle Cell Lymphoma Network aimed to investigate whether the introduction of high-…
European Mantle Cell Lymphoma Network aimed to investigate whether the introduction of high-…
[PDF][PDF] Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche
…, Y Kunisaki, J Lacombe, SA Armstrong, U Dührsen… - Cell stem cell, 2014 - cell.com
Perivascular mesenchymal stem and progenitor cells (MSPCs) are critical for forming a
healthy hematopoietic stem cell (HSC) niche. However, the interactions and influence of acute …
healthy hematopoietic stem cell (HSC) niche. However, the interactions and influence of acute …
[HTML][HTML] Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma
Purpose Outcomes for patients with diffuse large B-cell lymphoma remain heterogeneous,
with existing methods failing to consistently predict treatment failure. We examined the …
with existing methods failing to consistently predict treatment failure. We examined the …
Inflammatory reactions and severe neutropenia in mice lacking the transcriptional repressor Gfi1
The transcriptional repressor Gfi1 is a nuclear zinc-finger protein expressed in T-cell precursors
in the thymus and in activated mature T lymphocytes 1, 2, 3, 4. Previous experiments …
in the thymus and in activated mature T lymphocytes 1, 2, 3, 4. Previous experiments …